OVERSEA CHINESE BANKING Corp Ltd Has $1.13 Million Stock Holdings in Bristol Myers Squibb Company $BMY

OVERSEA CHINESE BANKING Corp Ltd raised its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 299.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 20,914 shares of the biopharmaceutical company’s stock after acquiring an additional 15,678 shares during the quarter. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Bristol Myers Squibb were worth $1,128,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in BMY. Brighton Jones LLC lifted its stake in Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 2,786 shares during the last quarter. United Bank lifted its stake in Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 3,277 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Bristol Myers Squibb in the second quarter worth $221,000. Finally, Nebula Research & Development LLC acquired a new stake in shares of Bristol Myers Squibb in the second quarter worth $405,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.05% of the company’s stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays upgraded BMY to a Buy, citing reasons that support upside versus peers — a clear near-term catalyst for positive investor flows. Bristol-Myers Squibb (BMY) Receives a Buy from Barclays
• Positive Sentiment: A momentum/long-term interest piece argues BMY is a top momentum stock, which can draw growth-oriented buyers and support multiple expansion if sentiment improves. Why Bristol Myers Squibb (BMY) is a top momentum stock for the long term
• Positive Sentiment: Zacks published bullish commentary framing BMY as a strong value pick vs. peers, highlighting relative valuation and an improving earnings outlook — supportive for value-oriented investors. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock
• Positive Sentiment: Zacks also ran a comparative piece arguing BMY stacks up better than Gilead on valuation and growth potential, which can attract investors rotating within large-cap biopharma. Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
• Neutral Sentiment: Bernstein kept a Hold on BMY; that maintains neutral analyst pressure (no clear push to buy or sell). Investors may wait for further catalyst or clearer conviction. Bernstein Remains a Hold on Bristol-Myers Squibb (BMY)
• Neutral Sentiment: Geronimo Power’s new Blevins solar project will supply power to two counterparties including Bristol Myers Squibb — a modest ESG / cost-stability positive but unlikely to move the stock materiality. Geronimo Power commences operations at 270MW Blevins Solar Project
• Neutral Sentiment: Two market reports highlight BMY’s involvement in vulvar cancer and Sjögren’s syndrome treatment landscapes — useful pipeline context but not immediate stock-moving clinical data. Vulvar Cancer Market Global and Regional Analysis Report 2025-2035 Sjogren’s Syndrome Market Analysis Report 2025-2035
• Negative Sentiment: A Wall Street roundup flagged downbeat forecasts for select stocks (including BMY in context), which can pressure the stock by amplifying risk-off positioning among institutional desks. 1 Unpopular Stock That Should Get More Attention and 2 We Question

Analyst Ratings Changes

A number of analysts have recently weighed in on BMY shares. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Guggenheim restated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Piper Sandler restated an “overweight” rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Leerink Partners boosted their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Finally, Barclays started coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Trading Down 0.9%

Shares of BMY stock opened at $58.84 on Thursday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The firm’s fifty day simple moving average is $59.74 and its 200 day simple moving average is $53.95. The firm has a market capitalization of $120.13 billion, a P/E ratio of 17.05, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same period last year, the firm posted $1.67 EPS. The company’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.28 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. Bristol Myers Squibb’s payout ratio is 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.